Literature DB >> 30935664

Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study.

Neema P Mayor1, James D Hayhurst2, Thomas R Turner1, Richard M Szydlo3, Bronwen E Shaw4, Will P Bultitude1, Jex-Ray Sayno2, Franco Tavarozzi2, Katy Latham2, Chloe Anthias5, James Robinson1, Henny Braund2, Robert Danby6, Julia Perry7, Marie C Wilson7, Adrian J Bloor8, I Grant McQuaker9, Stephen MacKinnon10, David I Marks11, Antonio Pagliuca12, Michael N Potter13, Victoria T Potter12, Nigel H Russell14, Kirsty J Thomson10, J Alejandro Madrigal1, Steven G E Marsh15.   

Abstract

HLA matching at an allelic-level resolution for volunteer unrelated donor (VUD) hematopoietic cell transplantation (HCT) results in improved survival and fewer post-transplant complications. Limitations in typing technologies used for the hyperpolymorphic HLA genes have meant that variations outside of the antigen recognition domain (ARD) have not been previously characterized in HCT. Our aim was to explore the extent of diversity outside of the ARD and determine the impact of this diversity on transplant outcome. Eight hundred ninety-one VUD-HCT donors and their recipients transplanted for a hematologic malignancy in the United Kingdom were retrospectively HLA typed at an ultra-high resolution (UHR) for HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 using next-generation sequencing technology. Matching was determined at full gene level for HLA class I and at a coding DNA sequence level for HLA class II genes. The HLA matching status changed in 29.1% of pairs after UHR HLA typing. The 12/12 UHR HLA matched patients had significantly improved 5-year overall survival when compared with those believed to be 12/12 HLA matches based on their original HLA typing but were found to be mismatched after UHR HLA typing (54.8% versus 30.1%, P = .022). Survival was also significantly better in 12/12 UHR HLA-matched patients when compared with those with any degree of mismatch at this level of resolution (55.1% versus 40.1%, P = .005). This study shows that better HLA matching, found when typing is done at UHR that includes exons outside of the ARD, introns, and untranslated regions, can significantly improve outcomes for recipients of a VUD-HCT for a hematologic malignancy and should be prospectively performed at donor selection.
Copyright © 2019 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HLA matching; Next-generation sequencing; Survival; Ultra-high resolution HLA typing; Unrelated donor hematopoietic cell transplantation

Year:  2019        PMID: 30935664     DOI: 10.1016/j.bbmt.2018.12.768

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  16 in total

1.  Selection of matched unrelated donors moving forward: from HLA allele counting to functional matching.

Authors:  Katharina Fleischhauer
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

2.  Role of HLA-DP Expression in Graft-Versus-Host Disease After Unrelated Donor Transplantation.

Authors:  Effie W Petersdorf; Mats Bengtsson; Dianne De Santis; Valerie Dubois; Katharina Fleischhauer; Ted Gooley; Mary Horowitz; J Alejandro Madrigal; Mari Malkki; Caroline McKallor; Yasuo Morishima; Machteld Oudshoorn; Stephen R Spellman; Jean Villard; Phil Stevenson; Mary Carrington
Journal:  J Clin Oncol       Date:  2020-06-01       Impact factor: 44.544

3.  Genotyping of canine MHC gene DLA-88 by next-generation sequencing reveals high frequencies of new allele discovery and gene duplication.

Authors:  Chul-Woo Pyo; Michael A Harkey; Beverly Torok-Storb; Rainer Storb; Ruihan Wang; Alexander S Thomas; Wyatt C Nelson; Daniel E Geraghty
Journal:  HLA       Date:  2022-08-09       Impact factor: 8.762

4.  Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation.

Authors:  Neema P Mayor; Tao Wang; Stephanie J Lee; Michelle Kuxhausen; Cynthia Vierra-Green; Dominic J Barker; Jeffrey Auletta; Vijaya R Bhatt; Shahinaz M Gadalla; Loren Gragert; Yoshihiro Inamoto; Gerald P Morris; Sophie Paczesny; Ran Reshef; Olle Ringdén; Bronwen E Shaw; Peter Shaw; Stephen R Spellman; Steven G E Marsh
Journal:  J Clin Oncol       Date:  2021-04-09       Impact factor: 50.717

Review 5.  The IPD Project: a centralised resource for the study of polymorphism in genes of the immune system.

Authors:  Giuseppe Maccari; James Robinson; John A Hammond; Steven G E Marsh
Journal:  Immunogenetics       Date:  2019-10-22       Impact factor: 2.846

6.  HLA-B leader and survivorship after HLA-mismatched unrelated donor transplantation.

Authors:  Effie W Petersdorf; Philip Stevenson; Mats Bengtsson; Dianne De Santis; Valerie Dubois; Ted Gooley; Mary Horowitz; Katharine Hsu; J Alejandro Madrigal; Mari Malkki; Caroline McKallor; Yasuo Morishima; Machteld Oudshoorn; Stephen R Spellman; Jean Villard; Mary Carrington
Journal:  Blood       Date:  2020-07-16       Impact factor: 25.476

7.  Common, intermediate and well-documented HLA alleles in world populations: CIWD version 3.0.0.

Authors:  Carolyn K Hurley; Jane Kempenich; Kim Wadsworth; Jürgen Sauter; Jan A Hofmann; Daniel Schefzyk; Alexander H Schmidt; Pablo Galarza; Maria B R Cardozo; Malgorzata Dudkiewicz; Lucie Houdova; Pavel Jindra; Betina S Sorensen; Latha Jagannathan; Ankit Mathur; Tiina Linjama; Tigran Torosian; Rafi Freudenberger; Anastasios Manolis; John Mavrommatis; Nezih Cereb; Sigal Manor; Nira Shriki; Nicoletta Sacchi; Reem Ameen; Raewyn Fisher; Heather Dunckley; Irene Andersen; Ahmed Alaskar; Mohsen Alzahrani; Ali Hajeer; Dunia Jawdat; Grazia Nicoloso; Pawinee Kupatawintu; Louise Cho; Ashminder Kaur; Mats Bengtsson; Jason Dehn
Journal:  HLA       Date:  2020-01-31       Impact factor: 4.513

Review 8.  Immunogenetics in stem cell donor registry work: The DKMS example (Part 1).

Authors:  Alexander H Schmidt; Jürgen Sauter; Daniel M Baier; Jessica Daiss; Andreas Keller; Anja Klussmeier; Thilo Mengling; Gabi Rall; Tobias Riethmüller; Gerhard Schöfl; Ute V Solloch; Tigran Torosian; David Means; Helen Kelly; Latha Jagannathan; Patrick Paul; Anette S Giani; Sabine Hildebrand; Stephan Schumacher; Jan Markert; Monika Füssel; Jan A Hofmann; Thomas Schäfer; Julia Pingel; Vinzenz Lange; Johannes Schetelig
Journal:  Int J Immunogenet       Date:  2020-01-06       Impact factor: 1.466

Review 9.  T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies.

Authors:  Valérie Janelle; Caroline Rulleau; Simon Del Testa; Cédric Carli; Jean-Sébastien Delisle
Journal:  Front Immunol       Date:  2020-02-21       Impact factor: 7.561

10.  A diploid assembly-based benchmark for variants in the major histocompatibility complex.

Authors:  Chen-Shan Chin; Justin Wagner; Qiandong Zeng; Erik Garrison; Shilpa Garg; Arkarachai Fungtammasan; Mikko Rautiainen; Sergey Aganezov; Melanie Kirsche; Samantha Zarate; Michael C Schatz; Chunlin Xiao; William J Rowell; Charles Markello; Jesse Farek; Fritz J Sedlazeck; Vikas Bansal; Byunggil Yoo; Neil Miller; Xin Zhou; Andrew Carroll; Alvaro Martinez Barrio; Marc Salit; Tobias Marschall; Alexander T Dilthey; Justin M Zook
Journal:  Nat Commun       Date:  2020-09-22       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.